SLC5A2 and diabetic kidney disease: The purpose of this study was to investigate the hypothesis that inhibition of SGLT2 by dapagliflozin ameliorates glucose homeostasis while preserving β-cell mass, and retards the progression of diabetic nephropathy by inhibiting inflammation and oxidative stress in a mouse model of type 2 diabetes and obesity.